Assessment Of Safety And Efficacy Of SU11248 In Patients With Metastatic Colorectal Cancer Who Have Failed Selected Previous Treatments.

Phase 2

Completed

• Conditions: Colorectal Neoplasms

• Registration Number: NCT00077987
• Lead Sponsor: Pfizer

Brief Summary

Assessment of safety and efficacy of SU11248 in patients with metastatic colorectal cancer who have failed selected previous treatments.

Detailed Description

Not available

Study Timeline

• Study Start: 2003-12
• Study First Submitted: 2004-02-13
• Study First Submitted QC: 2004-02-17
• Study First Posted: 2004-02-18
• Study Completion: 2005-04
• Status Verified: 2005-10
• Last Update Submitted: 2007-01-09
• Last Update Posted: 2007-01-11

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 84

Inclusion Criteria

• Metastatic colorectal cancer
• Failed selected cancer therapies in the past.

Exclusion Criteria

• Prior treatment with tyrosine kinase inhibitors or VEGF inhibitors other than bevacizumab.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Primary Outcome Measures

Name	Time	Method
Anti-tumor efficacy

Secondary Outcome Measures

Name	Time	Method
Tumor control survival safety